Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.33
1% from low
Exchange
OTC Link
CS
NKGEN BIOTECH INC
No one on the platform currently holds NKGN.
No tracked institution reports a position in NKGN as of their last filing.
No one on the platform has traded NKGN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| NKGNNKGen Biotech, Inc. Common Stock | $0.01 | -0.00% | $653011 | — |
| BDRXBiodexa Pharmaceuticals Plc | $1.56 | +4.00% | $1M | — |
| BRNSBarinthus Biotherapeutics plc | $0.60 | +2.99% | $25M | — |
| BXRXQBaudax Bio, Inc. | $0.00 | +0.00% | $4359 | — |
| CCTGCCSC Technology International Holdings Limited Ordinary Shares | $0.79 | -0.99% | $912724 | — |
| CEROCERo Therapeutics Holdings, Inc. | $0.01 | -4.76% | $451124 | — |
| COYACoya Therapeutics, Inc. | $4.67 | -0.43% | $110M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NKGN fast track trials with no reports , no filing updates , optics on this company looking bad, pathetic actually.
View on StockTwits ↗$NKGN No idea what they are doing. No sec filing, no update on trial, I don’t even understand what stopping them from filing all pending sec forms so that we can atleast start trading on OTCQX.
View on StockTwits ↗$NKGN I wonder were the Panda Express Founder investor sits with this stock now ?
View on StockTwits ↗$NKGN never disappoints sinking to .001 and can’t purchase it.
View on StockTwits ↗$NKGN what’s going on today up to .15 with 75k + maybe a partnership or buyout in the works
View on StockTwits ↗$NKGN link to Dr. Song’s presentation last week. Interesting comments about the Japan market on the third from last page. https://nkgenbiotech.com/wp-content/uploads/2026/07/NKGen-2026-BioChina-PYS-non-video-version.pdf
View on StockTwits ↗$NKGN From Dr. Song’s Facebook, “Enjoying a glorious day in Tokyo with Rob Claar and the Heka Bio team who are working with NKGen Biotech to bring our NK cell therapy (troculeucel) to the Japanese market. Under Japan’s Yokohama declaration for regenerative medicine, we will soon begin commercial sales and treatment pending official inspections of our Korea and U.S. GMP facilities by the Japanese regulatory authorities. Our goal is to launch later this year.”
View on StockTwits ↗$NKGN https://nkgenbiotech.com/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-on-troculeucels-potential-in-alzheimers-disease-and-other-neurodegenerative-conditions/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.